zoeti spun lead global manufactur medic vaccin
livestock revenu companion anim revenu
report nice beat rais driven strong companion anim
growth despit livestock headwind african swine fever weak cattl
market zoetiss out-performance last coupl year driven
sever factor fdpainclud signific growth dermatolog portfolio
exceed street expect see pathway next
coupl year similar perform driven continu product innov
simparica trio come market afford
multi-year first-mov advantag could drive substanti growth
monoclon antibodi mab treatment felin pain expect
believ blockbust sinc unmet need osteoarthr
treatment cat given good result base posit outlook
maintain buy rate rais price target
nutshel adjust ep higher consensu
higher estim revenu increas
higher consensu
higher estim fx headwind bp
oper growth organ cc revenu grew driven
price volum companion anim oper revenu growth
driven growth intern growth
livestock sale increas oper driven
increas intern growth gross margin increas
bp bp higher project
driven fx price product mix unit cost improv
remain ahead pack simparica trio product
launch horizon becom increasingli like zoeti
first market oral triple-combin parasiticid
simparica trio expect approv fda time launch
simparica trio receiv posit opinion ema
expect approv eu come month think
multi-year head start versu competitor also work tripl combo
competitor could struggl efficaci combin right dose
combin addit simparica trio regulatori review
countri canada australia brazil japan
submiss expect china mexico later year zoeti also file
monoclon antibodi mab treatment felin pain
product could approv canin mab treatment pain
expect follow think ztss develop pipelin drive
substanti growth next sever year product
blockbust potenti address certain unmet need especi cat
page
period except per share revenueadj epsrevenueadj epsrevenueadj epsrevenueadj previou revis compani data factset estim craig-hallum capit group llc
compani data craig-hallum capit group llc estim
companion anim sale continu impress zoetiss
companion anim busi revenu increas oper
exclud abaxi contribut driven increas sale key
dermatolog product well in-lin product like simparica
clavamox cerenia proheart addit launch apoquel
cytopoint new market well sale parasiticid
revolut simparica help bolster strong
companion anim sale grew oper
strong growth poultri offset continu livestock headwind
livestock sale return growth oper driven primarili
sale poultri product grew oper aid
competitor lack efficaci suppli constraint help off-set
continu headwind challeng dairi market weaker beef
cattl cattl remain pastur longer move feedlot
healthier heavier neg impact african swine fever
asf china oper
livestock china increas expect impact
asf year hog herd
china expect impact export brazil eu
expect increas
page
quarterli i/ varianceactualc-h estimate variancevari million except per expect revenu driven companion anim oper growthchang livestock sale grew oper abaxi ad growthchang margin expand bp due fx price growth product mix unit costgross partial off-set lower margin abaxi oper cost increas oper due abaxi increas compensation-rel expens invest support futur growth amort oper oper oper effect tax rate decreas due discret tax benefit partial off-set tax global intang low tax guilti tax net net incom attr incom attribut net incom increas attribut revenu growth higher grossnet lower effect tax rate dilut ebitda analysi oper incom attr
companion anim revenu increas y/i
oper lower estim
constant currenc basi dog cat product sale increas
equin product sale zoetiss dermatolog
franchis continu drive strong growth sale simparica
apoquel sale increas y/i consist
 intern sale
cytopoint sale increas y/i driven
sale intern sale
simparica revenu increas y/i driven
 intern market
revenu increas y/i
higher estim oper intern revenu
increas partial off-set neg fx impact
livestock revenu decreas
higher estim driven
oper growth vs estim fx
bp headwind livestock sale larg driven
growth compani poultri portfolio primarili vaccin
companion anim revenu increas y/i
lower estim
driven oper growth vs estim partial
off-set bp fx headwind strong companion anim
growth driven contribut abaxi increas
sale simparica well increas sale apoquel
geograph perspect oper cc growth strongest
brazil due favor y/i comparison driven
growth companion anim sale growth livestock
abaxi mexico driven companion anim growth
zoeti inc page
varianc varianc except per share c-h estimate con actualto c-h estimate c-h estimate expect revenu driven strong companion anim product sale y/i sale abaxi strong perform apoquel cytopoint parasiticid companion oper growth driven abaxi key dermatolog product number ofy/i in-lin product simparica clavamox cerenia proheart sale grew driven antibiot altern poultri modest growth swine y/i cattl product sale modestli due weak dairi beef ernat grew operationallyy/i oper companion grew oper driven sale apoquel cytopoint parasiticid y/i stronghold contribut abaxi oper grew oper driven poultri portfolio w/ higher vaccin sale y/i cattl sale increas due favor y/i comp brazil swine sale wereoper y/i growth vaccin off-set on-going weak china african swine fever contract revenu grew oper basi organ growth fx impact y/i ad growth price contribut volum ad dermatologyoper sale contribut growth new product ad in-lin product compani data factset estim craig-hallum capit group llc
growth livestock oper revenu china decreas due
neg impact african swine fever
revenu speci continu reflect strong growth companion anim
product sale apoquel cytopoint simparica revolut
driven revenu dog cat percent total
sale cattl product challeng cattl still account
total revenu swine revenu
follow poultri aquacultur
product sale account total revenu
revenu ep guidanc increas follow strong result zoeti
increas revenu guidanc rang
primarili attribut continu perform
compani companion anim busi favor fx adjust
ep guidanc increas rang
said manag expect impact sever factor includ
tougher comparison due one extra revenu day challeng
african swine fever weak dairi beef market increas
expens expand field forc support futur product launch proheart
simparica trio monoclon antibodi pain cat recoveri
brazilian trucker strike boost revenu
zoeti inc page
otherothertot million australiabrazilcanadachinafr germani italyjapanmexicospainuk compani report craig-hallum capit grouprev guidancepreviousupd million except per share fy oper cost sale sg interest expens andoth tax rate adj dilut net signific item andacquisition-rel dilut compani data factset estim chlm estim
increas price target base ev/ebitda multipl
ebitda estim project net debt
share outstand price target also support appli price-to-earnings multipl
ep estim valuat support
long-term discount cash flow dcf valuat analysi use termin growth rate
wacc
believ invest zoeti involv follow risk
increas restrict ban use antibiot use growth promot
livestock fda work phase-out use medic import antibacteri
anim feed growth promot chang produc behavior increas regul
could advers impact zoetiss antibacteri product sale
lead chang underli market demand product
chang util product relat protein consumpt chang
consum spend habit diet protein consumpt could advers effect
zoeti busi
infecti diseas outbreak variou infecti diseas avian flu swine flu
etc could lead cull herd reduct use product
cash pay busi therefor chang economi input cost commod
price could neg impact produc abil buy product
industri consolid increas competit continu consolid
anim health industri could lead increas competit result price pressur
could neg impact margin profit
foreign currenc fluctuat approxim zoeti busi deriv
outsid creat foreign currenc risk
zoeti inc page
page
zoetiscraig-hallum capit groupincom statement mm except per share kevin ellich oper oper oper tax net incom attr non-controlling incom attribut ebitda analysi oper incom attribut non-controlling oper incom attribut compani report craig-hallum capit group llc estimatesaugust requir disclosur
